GlassScriptPhysician profile
Mohamed K Adenwalla
NPI 1184679524
$4,449.33
in general payments reported to CMS, 2019-2025
15 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $53.29 · 2021: $749 · 2022: $509 · 2023: $697 · 2024: $553 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $1,095.06 | 2019-2023 | Iluvien |
| Alcon Vision LLC | $717.43 | 2021-2025 | Constellation, Ngenuity |
| Abbvie INC. | $648.50 | 2022-2025 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $575.66 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $390.63 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $296.49 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $291.77 | 2022-2025 | Syfovre |
| Glaukos Corporation | $167.90 | 2024-2025 | Istent Infinite, Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $88.33 | 2025 | Stellaris |
| Notal Vision, INC. | $48.10 | 2022 | |
| Coherus Oncology, INC. | $47.50 | 2022-2023 | |
| Allergan, INC. | $36.90 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $17.03 | 2025 | Iluvien |
| Carl Zeiss Meditec, INC. | $15.63 | 2019 | |
| Eyepoint US, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Adenwalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.